How Warehouses And 3PLs Apply For An EU Wholesale Distribution Authorisation (WDA)
EU Wholesale Distribution Authorisation (WDA)
Definition
Authorisation from a national competent authority required for wholesale distribution of medicinal products in the EEA.
Overview
EU Wholesale Distribution Authorisation (WDA) is an authorisation from a national competent authority required for wholesale distribution of medicinal products in the EEA. Applying for a WDA is a structured process that tests whether your facility, systems and personnel meet national and EU distribution standards.
For warehouse managers and 3PL operators the application process starts with planning: decide whether your organisation will act as the wholesale distributor (and therefore needs a WDA), or operate as a service provider under a customer’s authorisation. If a WDA is required, prepare documentation that proves your compliance with GDP and national application requirements.
Pre-Application Steps
- Define Activities: List the exact wholesale activities (storage, repackaging, export, distribution) and product types (human, veterinary, cold-chain biologics) you plan to handle.
- Assign A Responsible Person: Identify a qualified individual who will be accountable for GDP compliance; their qualifications and role must be documented.
- Gap Analysis: Perform an internal GDP gap assessment against EudraLex and national guidance to identify corrective actions before application.
Documentation You Will Need
Typical dossiers include organisational charts, premises layout, SOPs covering receipt, storage, dispatch, returns, recalls and complaints, temperature mapping and validation reports, transport agreements, personnel training records, risk assessments, and details of IT and inventory systems. The NCA will expect evidence of a quality management system and documented oversight of subcontractors.
Facility And Technical Requirements
Inspectors will review physical controls: segregation of products, pest control, secure access, appropriate racking, validated cold rooms for temperature-sensitive products, continuous temperature monitoring with alarms and documented calibration histories. IT systems for traceability and batch records, and secure record storage are also evaluated.
The Application Process And Timeline
Applications are submitted to the national competent authority in the member state where the activities occur. Processing times vary by country—some NCAs publish target timelines but expect several weeks to a few months. Expect at least one pre-authorisation inspection. If deficiencies are found, the NCA will request corrective actions; a WDA may be granted once satisfactory evidence is provided.
Inspection Preparation
- Mock Audits: Conduct internal or third-party mock inspections to prepare personnel and documentation.
- Records Readiness: Ensure batch traceability, shipment records and temperature logs are immediately retrievable.
- Personnel Briefing: Train staff to answer inspector queries concisely and to demonstrate procedures during walkthroughs.
Costs And Ongoing Obligations
Costs include application fees charged by NCAs, investment to bring facilities up to GDP standard, staff training and possible consultant fees. After authorisation there are ongoing obligations: maintain GDP compliance, report significant changes, allow inspections, submit periodic returns if required, and renew or vary the authorisation as activities change.
Cross-Border Considerations For Multi-Site Operations
If you operate in multiple EEA countries you will generally need a WDA in each jurisdiction where wholesale activities occur. Some companies centralise quality oversight while maintaining site-specific authorisations; others use local partners. Where distribution crosses borders frequently, harmonise SOPs across sites and ensure contract clauses define responsibilities for GDP and recall management.
Common Pitfalls And How To Avoid Them
- Incomplete Documentation: Ensure SOPs and records match actual practice; discrepancies are a common inspection finding.
- Inadequate Cold-Chain Evidence: Temperature mapping and validation are often underdeveloped—invest in robust monitoring and documented corrective actions.
- Unclear Contracting: Contracts that fail to clarify which party holds the WDA and who controls GDP tasks create regulatory risk; make responsibilities explicit.
In short, the EU Wholesale Distribution Authorisation (WDA) requires careful preparation: define activities, close GDP gaps, document systems and facilities, appoint a Responsible Person, and prepare for inspection. With the right planning a warehouse or 3PL can secure a WDA and maintain compliant wholesale distribution across the EEA.
Sources And Additional Reading (3)
- Directive 2001/83/EC on the Community code relating to medicinal products for human use
“Directive 2001/83/EC on the Community code relating to medicinal products for human use.” EUR-Lex, https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A32001L0083.
- EudraLex — Volume 4: Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP)
“EudraLex — Volume 4: Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP).” European Commission, https://ec.europa.eu/health/documents/eudralex/vol-4_en.
- Directive 2011/62/EU on measures to prevent the entry into the legal supply chain of falsified medicinal products
“Directive 2011/62/EU on measures to prevent the entry into the legal supply chain of falsified medicinal products.” EUR-Lex, https://eur-lex.europa.eu/eli/dir/2011/62/oj.
More from this term
Looking for a 3PL?
Compare warehouses on Racklify and find the right logistics partner for your business.